| [1] |
De Leo S, Lee SY, Braverman LE. Hyperthyroidism[J]. Lancet, 2016, 388(10047):906-918.
doi: 10.1016/S0140-6736(16)00278-6
pmid: 27038492
|
| [2] |
Leger J, Carel JC. Diagnosis and management of hyperthyroidism from prenatal life to adolescence[J]. Best Pract Res Clin Endocrinol Metab, 2018, 32(4):373-386.
doi: S1521-690X(18)30062-9
pmid: 30086864
|
| [3] |
Mooij CF, Cheetham TD, Verburg FA, et al. 2022 European thyroid association guideline for the management of pediatric Graves' disease[J]. Eur Thyroid J, 2022, 11(1):e210073.
|
| [4] |
Sawicka B, Borysewicz-Sanczyk H, Wawrusiewicz-Kurylonek N, et al. Analysis of polymorphisms rs7093069-IL-2Ra, rs7138803-FAIM2, and rs1748033-PADI4 in the group of adolescents with autoimmune thyroid diseases[J]. Front Endocrinol(Lausanne), 2020, 11(10):544658.
|
| [5] |
Lane LC, Kus A, Bednarczuk T, et al. An intronic HCP5 variant is associated with age of onset and susceptibility to Graves disease in UK and Polish cohorts[J]. J Clin Endocrinol Metab, 2020, 105(9):e3277-3284.
doi: 10.1210/clinem/dgaa347
URL
|
| [6] |
Davies TF, Andersen S, Latif R, et al. Graves’ disease[J]. Nat Rev Dis Primers, 2020, 6(1):53.
doi: 10.1038/s41572-020-0195-8
|
| [7] |
De Luca F, Valenzise M. Controversies in the pharmacological treatment of Graves' disease in children[J]. Expert Rev Clin Pharmacol, 2018, 11(11):1113-1121.
doi: 10.1080/17512433.2018.1546576
URL
|
| [8] |
Wood CL, Cole M, Donaldson M, et al. Randomised trial of block and replace vs dose titration thionamide in young people with thyrotoxicosis[J]. Eur J Endocrinol, 2020, 183(6):637-645.
doi: 10.1530/EJE-20-0617
pmid: 33107439
|
| [9] |
Ohye H, Minagawa A, Noh JY, et al. Antithyroid drug treatment for Graves’ disease in children: A long-term retrospective study at a single institution[J]. Thyroid, 2014, 24(2):200-207.
doi: 10.1089/thy.2012.0612
URL
|
| [10] |
López-Valverde L, Domènech È, Roguera M, et al. Spontaneous reporting of adverse drug reactions in a pediatric population in a tertiary hospital[J]. J Clin Med, 2021, 10(23):5531.
doi: 10.3390/jcm10235531
URL
|
| [11] |
Azizi F, Takyar M, Madreseh E, et al. Long-term methimazole therapy in juvenile Graves’ disease: A randomized trial[J]. Pediatrics, 2019, 143(5):e20183034.
|
| [12] |
van Lieshout JM, Mooij CF, et al. Methimazole-induced remission rates in pediatric Graves’disease: A systematic review[J]. Eur J Endocrinol, 2021, 185(2):219-229.
doi: 10.1530/EJE-21-0077
pmid: 34061770
|
| [13] |
Léger J, Oliver I, Rodrigue D, et al. Graves' disease in children[J]. Ann Endocrinol (Paris), 2018, 79(6):647-655.
doi: S0003-4266(18)31214-9
pmid: 30180972
|
| [14] |
Silberstein EB, Alavi A, Balon HR, et al. The SNMMI practice guideline for therapy of thyroid disease with I-131 3.0[J]. J Nucl Med, 2012, 53(10):1633-1651.
doi: 10.2967/jnumed.112.105148
URL
|
| [15] |
Lutterman SL, Zwaveling-Soonawala N, Verberne HJ, et al. The efficacy and short- and long-term side effects of radioactive iodine treatment in pediatric Graves’ disease: A systematic review[J]. Eur Thyroid J, 2021, 10(5):353-363.
doi: 10.1159/000517174
pmid: 34540705
|
| [16] |
Annerbo M, Stalberg P, Hellman P. Management of Grave’s disease is improved by total thyroidectomy[J]. World J Surg, 2012, 36(8):1943-1946.
doi: 10.1007/s00268-012-1617-x
pmid: 22547016
|
| [17] |
Rivkees SA. Pediatric Graves’ disease: Management in the postpropylthiouracil era[J]. Int J Pediatr Endocrinol, 2014, 2014(1):10.
doi: 10.1186/1687-9856-2014-10
pmid: 25089127
|
| [18] |
Zaat AS, Derikx JPM, Zwaveling-Soonawala N, et al. Thyroidectomy in pediatric patients with Graves’ disease:A systematic review of postoperative morbidity[J]. Eur Thyroid J, 2021, 10(1):39-51.
|
